Ventac Partners portfolio company RhoVac reports it has been granted 2.5 million euro from Horizon 2020. For more information, please follow this link.
Ventac Partners portfolio company Idogen reports it has successfully established a novel method for the company's cell therapy. For more information, please follow this link.
Ventac Partners portfolio company RhoVac AB receives approval to start clinical phase IIb study in Denmark. For more information, please follow this link.
Ventac Partners portfolio company RhoVac reports positive results from the 12 months follow-up of the company’s phase I/II clinical study. For more information, please follow this link.
Ventac Partners portfolio company RhoVac announces that all patients completed the follow-up phase of the clinical phase I / II study. For more information, please follow this link.
Ventac Partners portfolio company, RhoVac, reports positive interim immune-results in the follow-up phase of company’s phase I/II clinical study. For more information, please follow this link.
